Navigation Links
PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering
Date:5/16/2013

SOUTH PLAINFIELD, N.J., May 16, 2013 /PRNewswire/ -- PTC Therapeutics, Inc., today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission ("SEC") relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not been determined.

(Logo:  http://photos.prnewswire.com/prnh/20010919/PTCLOGO )

J.P. Morgan and Credit Suisse are acting as joint book-running managers for the offering. Cowen and Company is acting as co-lead manager and Wedbush PacGrow Life Sciences as co-manager.

A registration statement relating to these securities has been filed with the SEC, but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any such state or jurisdiction.

The offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to the offering may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717; telephone: 866-803-9204; or Credit Suisse Securities (USA) LLC, or Credit Suisse Prospectus Department, One Madison Avenue, New York, NY 10010; telephone: 1-800-221-1037; email: newyork.prospectus@credit-suisse.com.

About PTC Therapeutics, Inc.

PTC is a biopharmaceutical company focused on the discovery, development and potential commercialization of orally administered small-molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are of central importance to proper cellular function. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare genetic disorders, oncology and infectious diseases.


'/>"/>
SOURCE PTC Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment of Solid Tumors at the Nanomedicine 2013 Meeting in Barcelona, Spain
2. Aratana Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering
3. Autoinjectors to 2018 Devices, Therapeutics, Markets, Strategies and Prospect
4. ADVENTRX Completes Name Change To "Mast Therapeutics, Inc."; New Ticker Symbol: "MSTX"
5. Autoinjectors to 2018 - Devices, Therapeutics, Markets, Strategies and Prospects
6. ADVENTRX Announces Corporate Name Change To "Mast Therapeutics, Inc."; Ticker Symbol Change To "MSTX"
7. Arno Therapeutics, Inc. Appoints Randy Thurman to the Board of Directors
8. Epigenetics Technology Market (Epigenomics, DNA Methylation, Histone Modifications, RNA Interference, Cancer Therapeutics, Personalized Medicine) (2012 - 2017)
9. Northwest Biotherapeutics, Inc. Announces Full Exercise of Over- Allotment Option
10. Cadence Pharmaceuticals Announces Termination of Option Agreement to Acquire Incline Therapeutics, Inc.
11. Caliber and ImmunGene Launch Valor Biotherapeutics, a Joint Venture to Develop Antibody-Interferon Fusion Therapeutics to Treat Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2020)... ... February 23, 2020 , ... ... Next,” an examination of the complex interplay between the brain, central nervous system ... first time at the International Association of Eating Disorders Professionals (iaedp™) 2020 Symposium ...
(Date:2/20/2020)... PLAINS, N.J. (PRWEB) , ... February 20, 2020 , ... ... new location at 27 Mountain Blvd. in Warren, NJ on Thursday, January 16 at ... staff and local elected officials for the ribbon-cutting ceremony. Members of the public and ...
(Date:2/20/2020)... ... February 20, 2020 , ... ... government program modernization, has been selected to perform Independent Verification and Validation ... (EOHHS) Health Insurance Exchange and Integrated Eligibility System (HIX/IES) project. , EOHHS, ...
Breaking Medicine Technology:
(Date:2/26/2020)... ... February 26, 2020 , ... Join the ... featured speaker Cristian Ionescu-Zanetti, PhD, Chief Technology Officer, Fluxion Biosciences as he provides ... a bench-top solution for high-sensitivity circulating tumor cell (CTC) enrichment and recovery from ...
(Date:2/23/2020)... ... 2020 , ... One of the stars of the long-running ... host of the informational program “Behind The Scenes.” “Behind The Scenes” educates its ... A soon to be aired episode will interview industry professionals about healthy eating ...
(Date:2/21/2020)... ... February 21, 2020 , ... Representatives with ... a 10 percent grand opening discount 0n its anti-colic portable baby bottle blender. ... Osmay Gonzalez, spokesperson for Baby Blendy LLC, a member of the Juvenile Products ...
(Date:2/21/2020)... ... 2020 , ... Cosmetic surgery continues to grow in popularity ... (ASPS). According to the ASPS, there were 17.7-million cosmetic procedures performed in the ... The American Society of Plastic Surgeons reported that some of the most popular ...
(Date:2/20/2020)... ... February 20, 2020 , ... R3 Medical Training announced its next joint injection ... how to perform injections for all large and small joints along with ultrasound needle ... videos. The best opportunity is to perform injections in a supervised setting. R3 Medical ...
Breaking Medicine News(10 mins):